Sol-Gel Technologies Ltd. (IL0011417206)
XSTU 
Summary
Sol-Gel Reports First Quarter 2025 Results
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025.
Sol-Gel Announces Reverse Share Split
NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share.
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO.
Sol-Gel Technologies Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Moshe Arkin CEO | XSTU Exchange | IL0011417206 ISIN |
| IL Country | 34 Employees | - Last Dividend | - Last Split | 23 Jan 2018 IPO Date |
Overview
Sol-Gel Technologies Ltd. is a specialty pharmaceutical company in the clinical stage, based in Israel, that specializes in the development and commercialization of innovative topical dermatological drugs. Leveraging its proprietary microencapsulation delivery system, the company is devoted to addressing unmet medical needs by creating new therapies with potential benefits over existing treatments. Formed in 1997, Sol-Gel has established a significant footprint in dermatology, driven by its robust pipeline of product candidates and a strategic collaboration with Perrigo. The company's primary focus is on diseases such as acne vulgaris, papulopustular rosacea, palmoplantar keratoderma, and rare skin conditions including Gorlin Syndrome.
Products and Services
- Twyneo
- Epsolay
- SGT-210
- SGT-610
- Erlotinib and Tapinarof
- Generic Topical Dermatological Drug Products
A groundbreaking, once-daily, non-antibiotic topical cream designed for the effective treatment of acne vulgaris. Twyneo has successfully completed Phase III clinical trials, demonstrating its potential as a leading acne treatment.
A novel, once-daily topical cream developed for treating papulopustular rosacea, Epsolay has completed Phase III clinical trials. Its microencapsulation delivery system uniquely positions it as a potentially transformative therapeutic option.
Currently in Phase I clinical trials, SGT-210 represents Sol-Gel's efforts to treat palmoplantar keratoderma, emphasizing the company's dedication to addressing rare and challenging dermatological conditions.
Targeting the rare disease Gorlin Syndrome, SGT-610 has completed Phase II clinical trials. This highlights Sol-Gel’s commitment to developing solutions for lesser-known, yet impactful, skin diseases.
These promising compounds are in development to treat other rare skin indications, showcasing Sol-Gel's broad approach to leveraging its microencapsulation technology for various therapeutic applications.
Alongside its innovative product pipeline, Sol-Gel is also involved in the development of generic topical dermatological drugs, aiming to offer effective and accessible treatment options within the broader market.
Contact Information
